Hadas Dvory‐Sobol

10.3k total citations · 1 hit paper
98 papers, 3.1k citations indexed

About

Hadas Dvory‐Sobol is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Hadas Dvory‐Sobol has authored 98 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Hepatology, 47 papers in Epidemiology and 46 papers in Infectious Diseases. Recurrent topics in Hadas Dvory‐Sobol's work include Hepatitis C virus research (58 papers), HIV/AIDS drug development and treatment (46 papers) and Hepatitis B Virus Studies (30 papers). Hadas Dvory‐Sobol is often cited by papers focused on Hepatitis C virus research (58 papers), HIV/AIDS drug development and treatment (46 papers) and Hepatitis B Virus Studies (30 papers). Hadas Dvory‐Sobol collaborates with scholars based in United States, France and New Zealand. Hadas Dvory‐Sobol's co-authors include Diana M. Brainard, John G. McHutchison, Hongmei Mo, Eric Lawitz, Michael D. Miller, Robert H. Hyland, Brian Doehle, Edward Gane, Nadir Arber and Evguenia S. Svarovskaia and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

Hadas Dvory‐Sobol

93 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

2022 164 citations Sorana Segal‐Maurer, Gary Sinclair et al. profile →

Peers

Countries citing papers authored by Hadas Dvory‐Sobol

Since Specialization

Citations

This map shows the geographic impact of Hadas Dvory‐Sobol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hadas Dvory‐Sobol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hadas Dvory‐Sobol more than expected).

Fields of papers citing papers by Hadas Dvory‐Sobol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hadas Dvory‐Sobol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hadas Dvory‐Sobol. The network helps show where Hadas Dvory‐Sobol may publish in the future.

Co-authorship network of co-authors of Hadas Dvory‐Sobol

This figure shows the co-authorship network connecting the top 25 collaborators of Hadas Dvory‐Sobol. A scholar is included among the top collaborators of Hadas Dvory‐Sobol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hadas Dvory‐Sobol. Hadas Dvory‐Sobol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV 2025 ·AIDS ·Debbie Hagins, Mezgebe Berhe, Gordon Crofoot, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, William E. Sanchez, Anita Scribner, Paul Benson, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Samir K. Gupta	0
2	577. Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir 2025 ·Open Forum Infectious Diseases ·Amy E. Colson, (unknown), Peter Ruane, Moti Ramgopal, Alexandra W. Dretler, Ronald Nahass, Gary Sinclair, Mezgebe Berhe, (unknown), Shanyu Liu, Stephanie O. Klopfer, Sharline Madera, Hadas Dvory‐Sobol, Martin S. Rhee, Elizabeth G. Rhee, Jared M. Baeten, Joseph J. Eron	2
3	Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial 2024 ·Clinical Infectious Diseases ·Onyema Ogbuagu, Jean‐Michel Molina, Ploenchan Chetchotisakd, Moti Ramgopal, William E. Sanchez, Jason Brunetta, Francesco Castelli, (unknown), (unknown), (unknown), Nicolas Margot, Hui Wang, Hadas Dvory‐Sobol, Martin S. Rhee, Sorana Segal‐Maurer	14
4	1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80 2023 ·Open Forum Infectious Diseases ·Princy Kumar, Deborah Goldstein, Richard L. Hengel, Aditya H. Gaur, (unknown), (unknown), Cheryl Newman, G. A. Saunders, Shanyu Liu, Hadas Dvory‐Sobol, Martin S. Rhee, Samir K. Gupta	2
5	Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial 2022 ·The Lancet HIV ·Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, (unknown), Anita Scribner, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Ellen Koenig	65
6	Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects 2019 ·Antiviral Research ·Bin Han, Ross Martin, Simin Xu, (unknown), Evguenia S. Svarovskaia, Hongmei Mo, Hadas Dvory‐Sobol	16
7	Tu1501 – Ledipasvir/Sofosbuvir for 8, 12, Or 24 Weeks is Safe and Effective in Patients Undergoing Dialysis 2019 ·Gastroenterology ·Wan‐Long Chuang, Tsung‐Hui Hu, Peter Buggisch, Christophe Moreno, Wei‐Wen Su, Luigi Biancone, James Spellman, (unknown), Robert H. Hyland, Sophia Lu, Svetlana Markova, Hadas Dvory‐Sobol, Anu Osinusi, Anuj Gaggar, Cheng‐Yuan Peng, Chen‐Hua Liu, Meghan E. Sise, Alessandra Mangia	1
8	Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1 2018 ·The Lancet. Gastroenterology & hepatology ·Marc Bourlière, Stuart C. Gordon, Eugene R. Schiff, Tram T. Tran, Natarajan Ravendhran, Charles Landis, Robert H. Hyland, Luisa M. Stamm, Jie Zhang, Hadas Dvory‐Sobol, G. Mani Subramanian, Diana M. Brainard, John G. McHutchison, Lawrence Serfaty, A. Thompson, Thomas Sepe, Michael P. Curry, K. Rajender Reddy, Michael P. Manns	18
9	No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients 2018 ·Journal of Hepatology ·Christoph Sarrazin, Curtis Cooper, Michael P. Manns, K. Rajender Reddy, Kris V. Kowdley, Stuart K. Roberts, Hadas Dvory‐Sobol, (unknown), Ross Martin, Grégory Camus, Brian Doehle, Luisa M. Stamm, Robert H. Hyland, Diana M. Brainard, Hongmei Mo, Stuart C. Gordon, Marc Bourlière, Stefan Zeuzem, Steven L. Flamm	41
10	Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems 2017 ·Virology ·Grégory Camus, Simin Xu, Bin Han, (unknown), Hadas Dvory‐Sobol, Yu Mei, Guofeng Cheng, Michael D. Miller, Brian Doehle, Hongmei Mo	11
11	NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome 2017 ·Journal of Hepatology ·Stefan Zeuzem, Masashi Mizokami, Stephen Pianko, Alessandra Mangia, Kwang‐Hyub Han, Ross Martin, Evguenia Svarovskaia, Hadas Dvory‐Sobol, Brian Doehle, Charlotte Hedskog, Chohee Yun, Diana M. Brainard, Steven Knox, John G. McHutchison, Michael D. Miller, Hongmei Mo, Wan‐Long Chuang, Ira M. Jacobson, Gregory J. Dore, Mark Sulkowski	149
12	Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies 2017 ·Journal of Hepatology ·Christophe Hézode, Nancy Reau, Evguenia S. Svarovskaia, Brian Doehle, (unknown), Hadas Dvory‐Sobol, Charlotte Hedskog, John McNally, Anu Osinusi, Diana M. Brainard, Michael D. Miller, Hongmei Mo, Stuart K. Roberts, Jacqueline G. O’Leary, Stephen D. Shafran, Stefan Zeuzem	63
13	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir 2016 ·Gastroenterology ·Christoph Sarrazin, Hadas Dvory‐Sobol, Evguenia S. Svarovskaia, Brian Doehle, Phillip S. Pang, (unknown), Julie Ma, Xiao Ding, Nezam H. Afdhal, Kris V. Kowdley, Edward Gane, Eric Lawitz, Diana M. Brainard, John G. McHutchison, Michael D. Miller, Hongmei Mo	163
14	Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1. 2016 ·Clinical Infectious Diseases ·Curtis Cooper, Susanna Naggie, Michael S. Saag, Jenny C. Yang, Luisa M. Stamm, Hadas Dvory‐Sobol, Lingling Han, Phillip S. Pang, John G. McHutchison, Douglas T. Dieterich, Mark Sulkowski	13
15	L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions 2015 ·The Journal of Infectious Diseases ·Evguenia S. Svarovskaia, Edward Gane, Hadas Dvory‐Sobol, Ross Martin, Brian Doehle, Charlotte Hedskog, Ira M. Jacobson, David R. Nelson, Eric Lawitz, Diana M. Brainard, John G. McHutchison, Michael D. Miller, Hongmei Mo	73
16	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation 2014 ·Gastroenterology ·Michael Charlton, Edward Gane, Michael P. Manns, Robert S. Brown, Michael P. Curry, Paul Y. Kwo, Robert J. Fontana, Richard Gilroy, Lewis Teperman, Andrew J. Muir, John G. McHutchison, William T. Symonds, Diana M. Brainard, Brian Kirby, Hadas Dvory‐Sobol, Jill Denning, Sarah Arterburn, Didier Samuel, Xavier Forns, Norah A. Terrault	254
17	1221 NO S282T MUTATION DETECTED BY DEEP SEQUENCING IN A LARGE NUMBER OF HCV PATIENTS WHO RECEIVED GS-7977 WITH RBV AND/OR GS-0938: THE QUANTUM STUDY 2013 ·Journal of Hepatology ·Evguenia Svarovskaia, Hadas Dvory‐Sobol, Viktoria Gontcharova, (unknown), (unknown), William T. Symonds, Jacob Lalezari, Michael D. Miller, Hongmei Mo	4
18	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial 2013 ·The Lancet ·Kris V. Kowdley, Eric Lawitz, (unknown), Tarek Hassanein, Mitchell Davis, Michael DeMicco, David Bernstein, Nezam H. Afdhal, John M. Vierling, Stuart C. Gordon, (unknown), Robert H. Hyland, Hadas Dvory‐Sobol, Di An, R. Hindes, Efsevia Albanis, William T. Symonds, M. Michelle Berrey, David R. Nelson, Ira M. Jacobson	227
19	Suppression of gastric cancer cell growth by targeting the β‐catenin/T‐cell factor pathway 2006 ·Cancer ·Hadas Dvory‐Sobol, Eyal Sagiv, Eliezer Liberman, Diana Kazanov, Nadir Arber	25
20	Oncogenic Transformation of Normal Enterocytes by Overexpression of Cyclin D1 2003 ·Digestive Diseases and Sciences ·Diana Kazanov, Itzhak Shapira, Marjorie Pick, (unknown), Eliezer Liberman, Varda Deutsch, (unknown), Hadas Dvory‐Sobol, Talya Kunik, Nadir Arber	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact